本帖最后由 老马 于 2012-1-13 21:20 编辑
; p( M* h6 i! I1 K5 @, B; I. }$ y
爱必妥和阿瓦斯丁的比较 I0 e, o: \+ z! ]" C6 }
# Z/ H+ o; q4 u* t5 p" Hhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/! }" C# Q* K, W0 x
. }+ e' c+ P9 |0 B0 g. f
8 K9 G G5 Z1 j7 Z; E" h5 V2 D+ p$ W
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/- Z. b# J. d0 v/ A" ^% ^
==================================================9 u- g7 N0 d8 p) M' o# Y2 F% `9 f9 L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
3 f6 G: `. h* F3 q7 M' s2 nPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.. d4 t" B5 K2 a7 l4 [6 m7 a0 I$ T7 p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.0 ]8 d2 e f, J
|
显身卡
4 {: [* g: W! J
